rolapitant
rolapitant is listed in the FDA National Drug Code directory with 1 NDC code, marketed under brand name including Varubi. Available dosage form: tablet.
Drug Details
- Generic Name
- rolapitant
- Brand Names
- Varubi
- Application Number
- NDA206500
- Sponsor
- TerSera Therapeutics LLC
- NDC Codes
- 1
- Dosage Forms
- TABLET
- Routes
- ORAL
- Active Ingredients
- ROLAPITANT HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE VARUBI ® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. VARUBI is a substance P/neurokinin 1 (NK1) receptor antagonist indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. ( 1 )